# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

B-Cell Lymphomas

Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 21-30 of 2194 results.
A Study to Investigate BGB-3111 in Chinese Participants With B-cell Lymphoma
Status: Active, not recruiting
Last Changed: Jul 14, 2020
First Received: Jun 16, 2017
Disease(s): B-cell Lymphoma
Intervention(s): BGB-3111
Locations: Beijing Cancer Hospital, Beijing, Beijing, China
Tongji Hospital, Tongji Medical College Huazhong Univ of Sci and Tch, Wuhan, Hubei, China
Jiangsu Province Hospital, Nanjing, Jiangsu, China
Tianjin Hematonosis Hospital, Tianjin, Tianjin, China
A Study to Compare the Bioequivalence and Safety of JHL1101 and Rituximab in CD20 Positive B Cell Lymphoma Patients
Status: Terminated
Last Changed: Jan 09, 2020
First Received: Sep 14, 2018
Disease(s): B Cell Lymphoma
Intervention(s): JHL1101, Rituximab
Locations: First Hospital of Shanxi Medical University, Taiyuan, Shanxi, China
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, Tianjin, China
CD19 CAR-T Expressing IL7 and CCL19 Combined With PD1 mAb for Relapsed or Refractory Diffuse Large B Cell Lymphoma
Status: Recruiting
Last Changed: Jun 29, 2020
First Received: May 11, 2020
Disease(s): Diffuse Large B-cell Lymphoma
Intervention(s): CD19-7×19 CAR-T plus PD1 monoclonal antibody
Locations: 2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
Cell Free DNA in Mature B-cell Lymphoma
Status: Recruiting
Last Changed: Sep 12, 2019
First Received: Sep 12, 2019
Disease(s): Mature B-Cell Lymphoma
Intervention(s): peripheral blood collection
Locations: Ruijin hospital, Shanghai, Shanghai, China
Autologous CD19 CAR T Cells in Relapsed or Refractory B-cell Lymphoma
Status: Active, not recruiting
Last Changed: Feb 25, 2019
First Received: Jul 22, 2016
Disease(s): B-cell Lymphoma
Intervention(s): autologous anti-CD19 CAR T cells
Locations: Peking University Cancer Hospital, Beijing, China
Epstein-Barr Virus Status in Diffuse Large B Cell Lymphoma
Status: Completed
Last Changed: Feb 12, 2014
First Received: Feb 12, 2014
Disease(s): Diffuse Large B-cell Lymphoma
Intervention(s): EBER
Locations: Samsung Medical Center, Seoul, Korea, Republic of
A Clinico-Pathologic Study of Primary Mediastinal B-Cell Lymphoma
Status: Completed
Last Changed: Aug 15, 2017
First Received: Jul 23, 2009
Disease(s): Primary Mediastinal B-Cell Lymphoma
Locations: A.O. SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
IRCCS Ospedale Oncologico, Bari, Italy
Policlinico S. Orsola Malpighi, Bologna, Italy
Ospedale Oncologico, Cagliari, Italy
Policlinico Careggi, Firenze, Italy
... and 16 other locations.
A Study to Evaluate Safety, Tolerability, PK and PD of HLX01 in Patients With CD20-positive B-cell Lymphomas
Status: Completed
Last Changed: Jul 19, 2017
First Received: Jul 14, 2017
Disease(s): B-cell Lymphomas
Intervention(s): HLX01
A Phase Ib Study of Oral Selinexor in Adult Patients With Relapsed/Refractory B-cell Lymphoma Receiving R-DHAOx or R-GDP
Status: Recruiting
Last Changed: Mar 13, 2020
First Received: Apr 18, 2016
Disease(s): B-cell Lymphoma
Intervention(s): selinexor, Rituximab, Dexamethasone, Oxaliplatin, Cisplatin, Cytarabine, Gemcitabine
Locations: Institut Jules Bordet, Bruxelles, Belgium
CHU Dijon, Dijon, France
CHRU de Lille - Hôpital Claude Huriez, Lille, France
CHU Montpellier - Hôpital Saint Eloi, Montpellier, France
CHU Nancy - Hôpital de Brabois, Nancy, France
... and 4 other locations.
R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma
Status: Recruiting
Last Changed: Jun 04, 2020
First Received: Jan 02, 2020
Disease(s): Diffuse Large B Cell Lymphoma
Intervention(s): Rituximab, Lenalidomide, Cyclophosphamide, Epirubicin, Vincristine, Prednisone, Methotrexate
Locations: Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university, Zhengzhou, Henan, China